
This segment explains the clinical significance of BRAF V600E–mutant NSCLC and highlights why early comprehensive genomic profiling is essential for identifying patients who benefit most from targeted BRAF/MEK inhibition.

This segment explains the clinical significance of BRAF V600E–mutant NSCLC and highlights why early comprehensive genomic profiling is essential for identifying patients who benefit most from targeted BRAF/MEK inhibition.